Shockwave Medical Announces Proposed Private Offering of $500.0 Million of Convertible Senior Notes
SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave…
Month: August 2023
Tango Therapeutics Announces $80 million Private Placement Financing
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology…
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the…
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the…
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of…
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of…
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer…
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer…
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
Ms. Gina Chapman Ms. Gina Chapman BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics,…
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
Ms. Gina Chapman Ms. Gina Chapman BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics,…
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…